Reports Q1 revenue $420.4M, consensus $409.35M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine Biosciences Reports First Quarter 2023 Financial Results
- JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
- Neurocrine price target raised to $110 from $108 at RBC Capital
- Neurocrine price target lowered to $127 from $131 at Citi
- Neurocrine price target lowered to $125 from $137 at UBS